EUnetHTA in few slides

EUnetHTA JA3 (2016-2020)

Aims to build a sustainable model for the scientific and technical cooperation on Health Technology Assessment (HTA) in Europe

80 partners consisting of national, regional and non-for-profit agencies that produce or contribute to HTA

Project Coordinator: Dutch National Health Care Institute (ZIN)




European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu





Different countries, different HTA practices


Data requirements in 8 countries + EUnetHTA







European Cooperation on HTA



Final objective of JA3

Set up practical conditions for a permanent (post-2020) collaboration

eunethta

EURORDIS.ORG


European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu





Structure

Organisational and Governance Structure







EUnetHTA Early Dialogue



- Work Package 4 for Evidence Generation is led by: HAS-GBA
 - Full members: HAS, GBA, NICE, AIFA, NIPN (HU)
 - Shared seat: RIZIV, ZIN
 - Alternate: RER (IT) for AIFA
- Expectations: carrying out > 30 EDs throughout JA3
 - 5 by Year 1 and 10 by Year 2
 - 1st ED ongoing (MS)





EUnetHTA Joint Assessment (REA)



- Work Package 5 for Joint Production is led by: LIB-ZIN-NIPHNO (Norway)
 - Expectations: 33 Joint Assessments throughout JA3
 - 2 by Year 1 and and 6 for Year 2 (2+3 in Year 1 and 2+6 in Year 2 on non-pharma)
- Outputs (Joint Reports)
 - Regorafenib [Stivarga] monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (available)
 - Alectinib [Alecensa] as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) (ongoing)
 - Midostaurin with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia (ongoing)



STEPS FORWARD (1) Parallel procedure: Early Dialogue (HTA) / Scientific Advice (EMA)

Key aspects

- It's an advice: not binding
- It addresses Regulatory and HTA issues

What's new

- An EARLY DIALOGUE WORKING PARTY has been established (EDWP), in charge of
- CENTRAL RECRUITEMENT of HTA Bodies (among partners and beyond) for each Parallel Procedure with EMA
- Level of engagement of HTA Bodies (COORDINATION) and Interaction with EMA



ANS LE VIF DU SUJET

• Prioritisation **EURORDIS.ORG**





Patient engagement recognised and integral part of the Agency's work

For Parallel Consultations - Individual patient experts identified

- through patient organisations <u>under the EMA framework for</u> interaction - EMA - patients - consumers (EMA/637573/2014)
- Capacity-building / training / briefing
- A pool of patients acting as experts in their disease and its management
- Invited to attend all teleconferences and the EMA HTA Applicant meeting;
- Also declare conflicts of interest, managing barriers to participation

Item on EMA-EUnetHTA workplan

Task force on patient involvement established at EUnetHTA level (cross workpackage)





STEPS FORWARD (2) EUnetHTA Task Force for Patient Engagement

Key aspects

- Gathering leaders of WP 4 and 5 on Early Dialogue and Joint Assessment
- Establishing new framework of interaction and guidelines for Col and Confidentiality
- Keeping patients' organisations up-to-date on the ongoing discussion



Main Issues

For EARLY DIALOGUE (so far)

- HTA experts have several weeks to become familiar with the dossier
- Patients receive the briefing book only few days ahead of the meeting
 - Mentorship is crucial
- Travel and accommodation expenses need to be prepaid

For EARLY DIALOGUE & JOINT ASSESSMENT

• There is still no standard procedure for patient engagement

For JOINT ASSESSMENT: NATIONAL UPTAKE

- Prevent Member States reassessing the same domain of the Joint Report?
- EURORDIS.ORG

10



"When we want your opinion, we'll give it to you."



Thank you for your attention

Matteo Scarabelli

matteo.scarabelli@eurordis.org

EURORDIS.ORG